Hormonal Selective Estrogen Receptor Modulator (SERM)FDA-approved medicinePrescription drug

Clomid (Clomiphene Citrate)

Clomiphene · Clomiphene Citrate

Evidence: Approved label. Example dose: finalize with a provider. Not a fact-check stamp.

25mg – 25-50 mg Oral Daily or EOD

Triphenylethylene DerivativeMixed Agonist/AntagonistRacemic (Enclomiphene + Zuclomiphene)FDA-Approved

Clomiphene citrate, marketed primarily as Clomid and Serophene, is an orally active selective estrogen receptor modulator (SERM) originally approved by the FDA in 1967 for the treatment of female infertility due to anovulation. It is a triphenylethylene derivative and a racemic mixture of two geometric isomers: enclomiphene (trans, the shorter-acting anti-estrogenic isomer responsible for most of the therapeutic effect) and zuclomiphene (cis, a longer-acting weakly estrogenic isomer that accumulates over repeated doses). Structurally it is closely related to tamoxifen and shares its mixed agonist/antagonist profile, though the isomer blend gives clomiphene a distinct pharmacokinetic and side-effect fingerprint.

Quick Start

Route

Oral

Start low

25mg Oral

Frequency

Daily or EOD

Timing

No food requirement - take with or without food

For PCT, 50mg/day for 2 weeks followed by 25mg/day for 2 weeks is a standard taper. For secondary hypogonadism, 25mg daily or 25mg EOD is often sufficient for eugonadal testosterone - lower doses reduce the risk of the characteristic mood and visual side effects. Draw baseline labs (LH, FSH, total and free testosterone, estradiol) before starting and recheck at 4-6 weeks. Report visual symptoms (blurred vision, light trails, flashes, floaters) immediately - these mandate discontinuation.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

25mg · Oral · Daily or EOD

conservative starter

25mg

Daily or EOD

Intermediate

Post-Cycle Therapy (PCT)

25-50 mg · Oral · Daily

human study · Katz et al. 2011 (BJU Int)

Commonly used after suppressive cycles. Taper the dose down during the final week.

25-50 mg

Daily

◆

How it works

Clomiphene is a racemic mixture of enclomiphene (trans-isomer, ~38% of the drug) and zuclomiphene (cis-isomer, ~62%), which differ markedly in both activity and pharmacokinetics. Enclomiphene is the primary anti-estrogenic actor - it competitively blocks estrogen receptors in the hypothalamus and pituitary, preventing estradiol negative feedback and disinhibiting pulsatile GnRH release, which raises LH and FSH output. Elevated LH stimulates Leydig cells to produce testosterone; elevated FSH supports Sertoli cells and spermatogenesis. Zuclomiphene has weak estrogenic agonist activity and a much longer half-life (~14 days vs ~10 hours for enclomiphene), so it accumulates across repeated doses and contributes the estrogenic side-effect profile (mood, visual, libido effects) that distinguishes Clomid from pure enclomiphene.

The tissue-selective activity pattern is similar to tamoxifen but distinct in emphasis - Clomid is a more potent HPT-axis stimulator at standard doses (50mg daily produces larger LH and FSH rises than 20mg tamoxifen), which is why it is often chosen when aggressive testosterone restoration is the goal, such as after prolonged anabolic suppression or in men with secondary hypogonadism who wish to preserve fertility rather than start TRT.

In breast tissue, Clomid acts as a partial antagonist but is generally less effective than Nolvadex for gynecomastia treatment - this is why a classic combined PCT runs both drugs (Clomid for maximal HPT stimulation, Nolvadex for receptor coverage at breast tissue). Clomid does not lower circulating estradiol - in fact estradiol typically rises during use because of the rising testosterone substrate available for aromatization.

What to expect

Early

Days 1–7

First 1-2 weeks: rapid LH and FSH response from the enclomiphene fraction; testosterone begins rising. Mood and libido changes may appear in either direction. Some users feel emotional flatness from the accumulating zuclomiphene isomer.

Mid

Weeks 2–4

Weeks 2-4: measurable testosterone recovery - often returning to pre-cycle baseline for men coming off a moderate anabolic cycle. This is the window to check labs (LH, FSH, total and free testosterone, E2) to confirm HPT restart and titrate dose.

Later

Weeks 4–12

Weeks 4-6: testosterone typically back in the physiological range for moderate-cycle recovery. Extended use (months for secondary hypogonadism) maintains eugonadal testosterone but warrants periodic breaks due to zuclomiphene accumulation and associated mood/visual risks.

Evidence

HumanStrong

AnimalModerate

In-vitroPresent

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

Clomiphene blocks estrogen negative feedback at the hypothalamus and pituitary, increasing gonadotropin secretion and endogenous testosterone production.

By blocking the negative feedback of estrogen on the hypothalamus and pituitary glands, clomiphene stimulates gonadotropin secretion, leading to increased endogenous testosterone production, which, in turn, improves sperm parameters and fertility and alleviates the symptoms of hypogonadism.

Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications. Pharmaceuticals (Basel, Switzerland) · 2024 · PMID 39338395

Evidence scope. Narrative review focused on male hypogonadism; supports the endocrine mechanism, not the page’s racemate percentages or isomer half-lives.

Long-term male users reported mood changes, blurred vision, and breast tenderness.

The most common side effects reported by patients treated more than 3 years included changes in mood in 5, blurred vision in 3 and breast tenderness in 2.

Long-Term Safety and Efficacy of Clomiphene Citrate for the Treatment of Hypogonadism. The Journal of urology · 2019 · PMID 31216250

Evidence scope. Retrospective study of men with hypogonadism; small adverse-event counts and no dose-specific risk.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Exact quick-start dose/frequency: 25 mg orally daily or every other day. Checked male abstracts used heterogeneous regimens; PMID 19359408 explicitly used 50 mg/day, not 25 mg daily/EOD.

Side effects & safety

Commonly reported

Mood changes - emotional flatness, irritability, or depressive symptoms (more common than with pure enclomiphene due to zuclomiphene)
Hot flashes (more common in women)
Mild nausea, especially first few days
Fatigue
Headache
Libido changes (can be up or down)

Less common & notes

Visual disturbances (blurred vision, floaters, light trails, flashes, light sensitivity) - dose-related, more common above 50mg/day; mandate immediate discontinuation as they are not always fully reversible.
Breast tenderness, hair thinning, dizziness, abdominal bloating or pain.
Rare but serious: venous thromboembolism (DVT, pulmonary embolism), ovarian hyperstimulation syndrome in women on ovulation induction protocols (OHSS), hepatotoxicity (rare, reversible), hypersensitivity reactions, pancreatitis (rare).
Long-term use in women is associated with a possible modest increase in ovarian cancer risk - this is not a men's-use concern but is part of the drug's FDA warnings.
The FDA-approved indication in women is capped at 6 cycles of use; extended off-label use in men warrants periodic breaks.

Pharmacokinetics

Illustrative plasma concentration · 20 d

Half-life

~5 days

Enclomiphene ~10 hours; zuclomiphene ~14 days

Peak · Tmax

6-8 hours

Elimination

~6 weeks

Enclomiphene clears in 2-3 days; zuclomiphene detectable for 4-6 weeks

Bioavailability

Well-absorbed orally (exact bioavailability not precisely characterized due to two-isomer blend)

Duration of action

Enclomiphene provides rapid HPT stimulation with daily dosing; zuclomiphene builds to steady state over 4-6 weeks and persists after discontinuation

Clearance

Hepatic (CYP2D6, CYP3A4). Fecal excretion predominates. Zuclomiphene accumulates across repeated daily doses due to its long half-life.

Storage. Store at controlled room temperature (20-25°C / 68-77°F). Protect from moisture and light. Keep in original container. Shelf life typically 4-5 years from manufacture date for tablets. Research-grade oral suspensions should be refrigerated after opening and used within 30-60 days. Keep out of reach of children.

Regulatory status

Prescription medication (Rx) in the United States. FDA-approved brands: Clomid (Sanofi-Aventis), Serophene (EMD Serono), Milophene. Generic clomiphene citrate is widely available. Not a controlled substance. Off-label use in men for PCT or secondary hypogonadism is common but legally requires a valid prescription. Research liquid forms marketed for research purposes are not FDA-regulated for human use. Internationally classified as a prescription drug in most jurisdictions.

Put it to work

Calculate, log & track

Open Clomid (Clomiphene Citrate) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Clomid (Clomiphene Citrate) in the app →

Go deeper

The guide & community

The complete Clomid (Clomiphene Citrate) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community